Ernexa Therapeutics (ERNAW) Total Non-Current Liabilities (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Total Non-Current Liabilities data on file, last reported at $3.6 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 66.79% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (down 66.79% YoY) and the FY2025 annual result came in at $3.4 million, down 1.94% from the prior year.
• Total Non-Current Liabilities improved to $3.6 million in Q1 2026, from $3.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $55.0 million in Q2 2024 to a low of $2.5 million in Q3 2025.
• A 5-year average of $21.9 million and a median of $11.0 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities jumped 593.43% — and 2025, when it slumped 95.31%.
• Tracing ERNAW's Total Non-Current Liabilities over 5 years: stood at $9.8 million in 2022, then jumped by 375.71% to $46.8 million in 2023, then plunged by 92.62% to $3.5 million in 2024, then dropped by 1.94% to $3.4 million in 2025, then advanced by 7.46% to $3.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $3.6 million (Q1 2026), $3.4 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.